Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver scarring in patients with fatty liver disease in a mid-stage trial.

Trucchio sees 48-week data as key for Phase 3 progress, while William Blair questions drug's impact on fibrosis and weight loss at 24 weeks.

Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety outcomes.

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis during a key MASH trial. While it helped with MASH resolution and weight ...

Altimmune said on Thursday its experimental obesity drug met the main goal of a mid-stage trial studying it as a potential treatment for a fatty liver disease. The drug, pemvidutide, showed a ...

Indeed, the company said that it would now concentrate its efforts on its ALT-801 peptide drug for fatty liver disease non-alcoholic steatohepatitis (NASH) and obesity.

Altimmune Shares Slump as Weight-loss Drug's Fatty Liver Trial Data Disappoints Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly ...

Fatty liver disease affects more than 1 in 3 adults and often has no symptoms. A new drug developed with Tulane researchers ...

About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases.

These positive results are expected to pave the way for Altimmune to engage with the FDA in an End-of-Phase 2 meeting. The ...